Tenofovir monotherapy versus tenofovir and entecavir combination therapy in patients with entecavir-resistant chronic hepatitis B with multiple drug failure: results of a randomised trial
Conclusions
TDF monotherapy for 48 weeks provided a virological response comparable to that of TDF and ETV combination therapy in patients infected with ETV-resistant HBV.
Trial registration number
ClinicalTrials.gov ID NCT01639092.
Source: Gut - Category: Gastroenterology Authors: Lim, Y.-S., Byun, K. S., Yoo, B. C., Kwon, S. Y., Kim, Y. J., An, J., Lee, H. C., Lee, Y. S. Tags: Hepatology Source Type: research